Yield10 Bioscience Researcher Dr. Frank Skraly to Present at the Plant Biology 2018 Conference
Dr. Skraly will describe the use of advanced metabolic modeling techniques as a means to model plant metabolism to identify and evaluate potential yield targets. During his presentation, Dr. Skraly will discuss two case studies. The first case models the mechanism of action for the novel yield trait C3003. The second case models the yield effect of a complex multi-gene pathway based on a synthetic carbon fixation pathway. Research suggests that the models can be used to project the range of yield improvement that can be attained with a crop yield gene target and compares the modeling results with experimental data from greenhouse or field studies using Yield10’s Camelina platform.
CCP1 is a gene found in certain algal species and is induced under low CO2 conditions. Yield10’s C3003 novel yield trait gene is based on CCP1. Yield10 has previously reported that expression of C3003 in Camelina has increased seed yield in a range from 7% to 23% under field conditions. The modeling outlined in the presentation explains why CCP1 may increase the efficiency of carbon fixation and result in yield improvements of approximately 20%. The modeling also suggests that CCP1 may benefit seed metabolism and identifies additional gene targets with the potential to further improve the yield impact of C3003. Yield10 is currently optimizing the deployment of C3003 and testing the trait in field tests of Camelina, canola and soybean.
Yield10 researchers engineered a complex multi-gene pathway into Camelina seeds to create an additional carbon fixation pathway. Modeling projects that the engineered pathway should increase the maximum theoretical seed yield in the engineered Camelina plants by 212%. Greenhouse results obtained for the pathway deployed in the best performing Camelina plants included increases in seed yield of 173%, 216% and 228%. These results were published in Plant Cell Reports in June 2018.
“Our modeling of new yield traits has been well correlated to the experimental results obtained under greenhouse conditions or in the field using our Camelina platform,” said Dr. Skraly. “The modeling is providing us with insights for deploying new seed yield traits and trait combinations that may boost seed yield by a significant margin over seed available commercially today.”
“Frank’s presentation highlights our metabolic engineering approach and the unique perspective it can provide to develop new ways to tackle the challenge of crop yield,” said
A copy of Dr. Skraly’s slide deck is available on the
For more information about the company, please visit www.yield10bio.com.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, the use of technology, including metabolic modeling techniques, to successfully identify targets and develop systems to increase crop yield, the amounts by which crop yield may be increased, if at all, the predictability of modeling outcomes for yield traits, the results of field tests of C3003 with Camelina, canola and soybean and the predictive value of the Camelina platform, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in
Fischtank Marketing and PR
Source: Yield10 Bioscience, Inc.